TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Polynovo ( (AU:PNV) ) is now available.
PolyNovo Limited has appointed Mr. Robert Douglas as a Non-Executive Director to its Board. Mr. Douglas brings over 35 years of experience in medical device technology and public company governance, with a strong background in digital health and international business expansion. His previous roles at ResMed and current position with Globus Medical highlight his expertise in patient data management and cloud technology, which are expected to benefit PolyNovo’s strategic growth and innovation efforts.
The most recent analyst rating on (AU:PNV) stock is a Buy with a A$1.62 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
More about Polynovo
PolyNovo is a disruptive medical technology company based in Melbourne, Australia, specializing in products that simplify the management of acute complex wounds. The company is known for its NovoSorb range of bio-resorbable polymers, which are used in various medical applications, including dermal scaffolds for wound regeneration. PolyNovo has treated over 84,000 patients across 46 countries and is focused on growth through new products, indications, and markets.
Average Trading Volume: 3,386,217
Technical Sentiment Signal: Sell
Current Market Cap: A$1.03B
For an in-depth examination of PNV stock, go to TipRanks’ Overview page.